Tags

Type your tag names separated by a space and hit enter

[Cariprazine, a new type - dopamine D₃ receptor preferring - partial agonist atypical antipsychotic for the treatment of schizophrenia and the primary negative symptoms].
Neuropsychopharmacol Hung. 2019 Sep; 21(3):103-118.NH

Abstract

Dopamine D₂ receptor partial agonists represent a new generation of atypical antipsychotics. Cariprazine, which has received centralized market authorization from the European Medicines Agency in 2017 for the treatment of adult patients with schizophrenia (including those with predominant negative symptoms of schizophrenia) differs from the other two partial agonist antipsychotics aripiprazole and brexpiprazole due to its unique features. Cariprazine is a dopamine D₃ preferring D₃/D₂ partial agonist with very similar dopamine receptor subtype selectivity as dopamine. It has proven efficacy in the treatment of positive and negative symptoms of schizophrenia, as well as for relapse prevention. Further phase-3 clinical studies proved the efficacy of cariprazine in the acute treatment of manic or mixed episodes associated with bipolar I disorder, as well as in bipolar depression. For the adjunctive treatment of major depressive disorder, phase 3 studies are in progress.

Authors+Show Affiliations

Laszlovszky I
Richter Gedeon Nyrt., Kutatási Igazgatóság, Orvostudományi főosztály, Budapest, Hungary. i.laszlovszky@richter.hu.
Kiss B
No affiliation info available
Barabassy A
No affiliation info available
Kapas M
No affiliation info available
Nemeth G
No affiliation info available

MeSH

Antipsychotic AgentsDepressive Disorder, MajorDopamine AgonistsHumansPiperazinesReceptors, Dopamine D3Schizophrenia

Pub Type(s)

Journal Article

Language

hun

PubMed ID

31537751

Citation

Laszlovszky, Istvan, et al. "[Cariprazine, a New Type - Dopamine D₃ Receptor Preferring - Partial Agonist Atypical Antipsychotic for the Treatment of Schizophrenia and the Primary Negative Symptoms]." Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet Lapja = Official Journal of the Hungarian Association of Psychopharmacology, vol. 21, no. 3, 2019, pp. 103-118.
Laszlovszky I, Kiss B, Barabassy A, et al. [Cariprazine, a new type - dopamine D₃ receptor preferring - partial agonist atypical antipsychotic for the treatment of schizophrenia and the primary negative symptoms]. Neuropsychopharmacol Hung. 2019;21(3):103-118.
Laszlovszky, I., Kiss, B., Barabassy, A., Kapas, M., & Nemeth, G. (2019). [Cariprazine, a new type - dopamine D₃ receptor preferring - partial agonist atypical antipsychotic for the treatment of schizophrenia and the primary negative symptoms]. Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet Lapja = Official Journal of the Hungarian Association of Psychopharmacology, 21(3), 103-118.
Laszlovszky I, et al. [Cariprazine, a New Type - Dopamine D₃ Receptor Preferring - Partial Agonist Atypical Antipsychotic for the Treatment of Schizophrenia and the Primary Negative Symptoms]. Neuropsychopharmacol Hung. 2019;21(3):103-118. PubMed PMID: 31537751.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Cariprazine, a new type - dopamine D₃ receptor preferring - partial agonist atypical antipsychotic for the treatment of schizophrenia and the primary negative symptoms]. AU - Laszlovszky,Istvan, AU - Kiss,Bela, AU - Barabassy,Agota, AU - Kapas,Margit, AU - Nemeth,Gyorgy, PY - 2019/9/21/entrez PY - 2019/9/21/pubmed PY - 2019/10/8/medline SP - 103 EP - 118 JF - Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology JO - Neuropsychopharmacol Hung VL - 21 IS - 3 N2 - Dopamine D₂ receptor partial agonists represent a new generation of atypical antipsychotics. Cariprazine, which has received centralized market authorization from the European Medicines Agency in 2017 for the treatment of adult patients with schizophrenia (including those with predominant negative symptoms of schizophrenia) differs from the other two partial agonist antipsychotics aripiprazole and brexpiprazole due to its unique features. Cariprazine is a dopamine D₃ preferring D₃/D₂ partial agonist with very similar dopamine receptor subtype selectivity as dopamine. It has proven efficacy in the treatment of positive and negative symptoms of schizophrenia, as well as for relapse prevention. Further phase-3 clinical studies proved the efficacy of cariprazine in the acute treatment of manic or mixed episodes associated with bipolar I disorder, as well as in bipolar depression. For the adjunctive treatment of major depressive disorder, phase 3 studies are in progress. SN - 1419-8711 UR - https://www.unboundmedicine.com/medline/citation/31537751/[Cariprazine_a_new_type___dopamine_D₃_receptor_preferring___partial_agonist_atypical_antipsychotic_for_the_treatment_of_schizophrenia_and_the_primary_negative_symptoms]_ DB - PRIME DP - Unbound Medicine ER -